Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Peritoneal dissemination in early gastric cancer: importance of the lymphatic route

  • 537 Accesses

  • 10 Citations

Abstract

The current paradigm concerning the mechanism of peritoneal dissemination of gastric cancer is that it occurs through an invasive process in which cancer cells directly penetrate the gastric wall and exfoliate into the peritoneal cavity. However, some experimental studies suggest the lymphatic route as an alternative. We present five early gastric cancer cases, which support this alternative pathway of peritoneal dissemination without direct invasion in the serosa. We investigated all patients with early gastric cancer who underwent curative gastrectomy between September 2002 and February 2015 at the Shizuoka Cancer Center, Japan. We examined them by intraoperative peritoneal lavage cytology and frozen section diagnosis of peritoneal nodules during laparotomy. Peritoneal dissemination was defined as peritoneal metastasis by positive cytology or histological diagnosis. Among 1509 early gastric cancers, five cases (0.3 %, 95 % CI 0.1–0.8 %) presented peritoneal dissemination detected by lavage cytology and frozen section diagnosis of peritoneal nodules. Histological examination revealed that the primary tumors invaded the submucosal layer using the lymphatic route, through which they metastasized to regional lymph nodes. Our data indicate that gastric cancer may give rise to peritoneal dissemination even at an early stage, probably through the lymphatic route without direct invasion into the serosa.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. doi:10.3322/caac.20107

  2. 2.

    Allum WH, Fielding JW (1990) Gastric cancer: a 25-year review. Br J Surg 77(3):353

  3. 3.

    Boku N (2011) Past and present achievements, and future direction of the Gastrointestinal Oncology Study Group (GIOSG), a Division of Japan Clinical Oncology Group (JCOG). Jpn J Clin Oncol 41(12):1315–1321

  4. 4.

    Thomassen I, van Gestel Y, van Ramshorst B, Luyer M, Bosscha K, Nienhuijs S, Lemmens V, de Hingh I (2014) Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 134(3):622–628

  5. 5.

    Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, Fushida S, Fujimura T, Nishimura G, Miwa K (1999) Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg 178(3):256–262

  6. 6.

    Bang Y-J, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang Y-K (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England) 376(9742):687–697

  7. 7.

    Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O’Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15(1):261–267

  8. 8.

    Wagner A, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig W (2010) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 3:CD004064

  9. 9.

    Ajani J, Moiseyenko V, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E (2007) Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25(22):3205–3209

  10. 10.

    Yang X-J, Huang C-Q, Suo T, Mei L-J, Yang G-L, Cheng F-L, Zhou Y-F, Xiong B, Yonemura Y, Li Y (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18(6):1575–1581

  11. 11.

    Gill R, Al Adra D, Nagendran J, Campbell S, Shi X, Haase E, Schiller D (2011) Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol 104(6):692–698

  12. 12.

    Glockzin G, Piso P (2012) Current status and future directions in gastric cancer with peritoneal dissemination. Surg Oncol Clin N Am 21(4):625–633

  13. 13.

    Glehen O, Gilly F, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder J, Lorimier G, Quenet F, Elias D (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370–2377

  14. 14.

    Kodera Y, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K, Morimoto T, Kato T (1999) Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 72(2):60–64

  15. 15.

    Hagiwara A, Takahashi T, Sawai K, Taniguchi H, Shimotsuma M, Okano S, Sakakura C, Tsujimoto H, Osaki K, Sasaki S (1993) Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res 53(3):687–692

  16. 16.

    Yamamoto M, Taguchi K, Baba H, Endo K, Kohnoe S, Okamura T, Maehara Y (2006) Peritoneal dissemination of early gastric cancer: report of a case. Surg Today 36(9):835–838

  17. 17.

    Kakushima N, Kamoshida T, Hirai S, Hotta S, Hirayama T, Yamada J, Ueda K, Sato M, Okumura M, Shimokama T, Oka Y (2003) Early gastric cancer with Krukenberg tumor and review of cases of intramucosal gastric cancers with Krukenberg tumor. J Gastroenterol 38(12):1176–1180

  18. 18.

    Japanese gastric cancer treatment guidelines 2010 (ver. 3) (2011). Gastric Cancer 14 (2):113-123

  19. 19.

    Japanese Gastric Cancer A (2011) Japanese classification of gastric carcinoma: 3rd english edition. Gastric Cancer 14(2):101–112. doi:10.1007/s10120-011-0041-5

  20. 20.

    Koike H, Ichikawa D, Kitamura K, Tsuchihashi Y, Yamagishi H (2004) Perinodal involvement of cancer cells in gastric cancer patients. Surgery 135(3):266–272

  21. 21.

    Etoh T, Sasako M, Ishikawa K, Katai H, Sano T, Shimoda T (2006) Extranodal metastasis is an indicator of poor prognosis in patients with gastric carcinoma. Br J Surg 93(3):369–373

  22. 22.

    Yoo CH, Noh SH, Shin DW, Choi SH, Min JS (2000) Recurrence following curative resection for gastric carcinoma. Br J Surg 87(2):236–242

  23. 23.

    Shimada S, Yagi Y, Shiomori K, Honmyo U, Hayashi N, Matsuo A, Marutsuka T, Ogawa M (2001) Characterization of early gastric cancer and proposal of the optimal therapeutic strategy. Surgery 129(6):714–719

  24. 24.

    Moriguchi S, Maehara Y, Korenaga D, Sugimachi K, Nose Y (1992) Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol 1(5):341–346

  25. 25.

    Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K (2008) D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359(5):453–462

  26. 26.

    Farley DR, Donohue JH, Nagorney DM, Carpenter HA, Katzmann JA, Ilstrup DM (1992) Early gastric cancer. Br J Surg 79(6):539–542

  27. 27.

    Guadagni S, Reed PI, Johnston BJ, De Bernardinis G, Catarci M, Valenti M, di Orio F, Carboni M (1993) Early gastric cancer: follow-up after gastrectomy in 159 patients. Br J Surg 80(3):325–328

  28. 28.

    Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, De Stefano A (2003) Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 90(9):1113–1119

  29. 29.

    Huang B, Sun Z, Wang Z, Lu C, Xing C, Zhao B, Xu H (2013) Factors associated with peritoneal metastasis in non-serosa-invasive gastric cancer: a retrospective study of a prospectively-collected database. BMC Cancer 13:57

  30. 30.

    Thomassen I, van Gestel Y, van Ramshorst B, Luyer M, Bosscha K, Nienhuijs S, Lemmens V, de Hingh I (2014) Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 134(3):622–628

  31. 31.

    Guadagni S, Catarci M, Kinoshitá T, Valenti M, De Bernardinis G, Carboni M (1997) Causes of death and recurrence after surgery for early gastric cancer. World J Surg 21(4):434–439

Download references

Acknowledgments

We thank Ms. Minako Ishii for sample collection.

Author information

Correspondence to Masao Yoshida.

Ethics declarations

All participants gave their written informed consent, and this study was approved by the institutional review board (institutional code number: 25-J42-25-1-3).

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yoshida, M., Sugino, T., Kusafuka, K. et al. Peritoneal dissemination in early gastric cancer: importance of the lymphatic route. Virchows Arch 469, 155–161 (2016). https://doi.org/10.1007/s00428-016-1960-7

Download citation

Keywords

  • Gastric cancer
  • Neoplastic processes
  • Neoplasm seeding
  • Lymphatic metastasis
  • Lymphatic vessels